Get the Stockscreener App
2.08
9.47%
0.18
Macrogenics Inc stock is traded at $2.08, with a volume of 926.34K.
It is up +9.47% in the last 24 hours and up +20.23% over the past month.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
See More
Previous Close:
$1.90
Open:
$1.92
24h Volume:
926.34K
Relative Volume:
0.77
Market Cap:
$131.58M
Revenue:
$139.77M
Net Income/Loss:
$-97.62M
P/E Ratio:
-1.3165
EPS:
-1.58
Net Cash Flow:
$-61.71M
1W Performance:
+8.33%
1M Performance:
+20.23%
6M Performance:
+7.22%
1Y Performance:
-10.34%
1-Day Range:
$1.89
$2.085
1-Week Range:
$1.81
$2.085
52-Week Range:
$0.9897
$2.485
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics Inc
Sector
Industry
Phone
301-251-5172
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
2.08 | 120.19M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Resumed | Barclays | Overweight |
| Nov-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-01-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-31-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| May-10-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-10-24 | Downgrade | Stifel | Buy → Hold |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| Apr-26-24 | Initiated | B. Riley Securities | Buy |
| Apr-09-24 | Upgrade | TD Cowen | Hold → Buy |
| Mar-04-24 | Reiterated | BTIG Research | Buy |
| Feb-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-22-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-14-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-18-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Jul-11-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-04-22 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-28-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-04-22 | Initiated | SMBC Nikko | Outperform |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Upgrade | Barclays | Underweight → Overweight |
| Dec-22-20 | Resumed | H.C. Wainwright | Buy |
| Aug-03-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-01-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-26-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Dec-19-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-19 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-21-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Guggenheim | Neutral |
| Feb-07-19 | Upgrade | Citigroup | Sell → Buy |
| Feb-07-19 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-06-19 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-04-19 | Downgrade | Citigroup | Neutral → Sell |
| Dec-10-18 | Downgrade | Raymond James | Outperform → Underperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| May-31-18 | Initiated | Evercore ISI | Outperform |
| Mar-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-31-17 | Initiated | Raymond James | Outperform |
View All
Macrogenics Inc Stock (MGNX) Latest News
MGNX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
MacroGenics (MGNX) director Jay Siegel to step down after 2026 meeting - Stock Titan
Whats the profit margin of MacroGenics IncEarnings Risk Report & Real-Time Volume Trigger Notifications - baoquankhu1.vn
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates C - GuruFocus
MacroGenics to Participate in Upcoming Investor Conferences - The Manila Times
Cancer drug developer MacroGenics lines up March investor talks - Stock Titan
Why is MacroGenics stock sinking Tuesday? - MSN
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates - MSN
MacroGenics stock falls after FDA places partial clinical hold By Investing.com - Investing.com South Africa
MacroGenics stock falls after FDA places partial clinical hold - Investing.com Nigeria
MacroGenics (MGNX) Faces FDA Setback with Partial Hold on Lorige - GuruFocus
MacroGenics stock drops after FDA partial hold (MGNX:NASDAQ) - Seeking Alpha
FDA Places Partial Clinical Hold on MacroGenics Trial - TipRanks
FDA Imposes Partial Clinical Hold on MacroGenics' (MGNX) Study - GuruFocus
Why Is MacroGenics Stock Sinking Tuesday? - Bitget
MacroGenics Pauses Enrollment Of Participants In LINNET Trial On FDA's Partial Clinical Hold - RTTNews
MacroGenics says FDA places partial clinical hold on Phase 2 LINNET study - TipRanks
FDA halts new enrollment in MacroGenics (NASDAQ: MGNX) LINNET study - Stock Titan
Macrogenics announces pausing of enrollment of new study participants in Linnet trial - marketscreener.com
MacroGenics Faces Partial Clinical Hold from FDA on LINNET Study of Lorigerlimab in Gynecologic Cancers - Quiver Quantitative
FDA halts new enrollment in cancer trial after severe side effects - Stock Titan
Panic Selling: Will MacroGenics Inc outperform the market in YEAR2025 Performance Recap & Weekly Setup with High ROI Potential - baoquankhu1.vn
Armistice Capital (MGNX) discloses 6.32M shares, 9.99% stake via Master Fund - Stock Titan
MacroGenics (NASDAQ: MGNX) SVP awarded RSUs, options and exercises units - Stock Titan
MacroGenics (MGNX) GC awarded 150,000 options and 25,000 RSUs - Stock Titan
Why MacroGenics Inc. stock is favored by pension fundsEarnings Beat & Accurate Entry/Exit Alerts - mfd.ru
Income Plays: Will MacroGenics Inc outperform the market in YEARPortfolio Return Report & Capital Protection Trade Alerts - baoquankhu1.vn
MGNX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Why MacroGenics Inc. stock remains a top recommendationJuly 2025 Opening Moves & Free Daily Entry Point Trade Alerts - mfd.ru
Scott Koenig increases MacroGenics (MGNX) stake via 15,831 RSU conversion - Stock Titan
MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Big Picture: Is Badger Meter Inc stock suitable for long term investing2025 Bull vs Bear & Weekly Market Pulse Alerts - baoquankhu1.vn
Incyte wins EU backing for MacroGenics-partnered cancer drug in GIT indication - Seeking Alpha
Aug Swings: Whats the fair value of Humacyte Inc Equity Warrant stockJuly 2025 Volume & Daily Chart Pattern Signals - baoquankhu1.vn
Retail Trends: What is the next catalyst for MacroGenics IncQuarterly Profit Report & Advanced Swing Trade Entry Plans - baoquankhu1.vn
MacroGenics (NASDAQ:MGNX) Stock Crosses Below 200-Day Moving Average – Should You Sell? - Defense World
MacroGenics (NASDAQ:MGNX) Stock Crosses Below 200-Day Moving AverageShould You Sell? - MarketBeat
Weekly Trades: Is MacroGenics Inc attractive for institutional investorsWeekly Market Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Will MacroGenics Inc outperform the market in YEAR2025 Biggest Moves & High Conviction Trade Alerts - baoquankhu1.vn
MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Analysts - MarketBeat
[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Is Via Renewables Inc impacted by rising ratesWeekly Trend Recap & Long-Term Growth Stock Strategies - baoquankhu1.vn
MacroGenics (NASDAQ:MGNX) Stock Price Crosses Above 50 Day Moving Average – What’s Next? - Defense World
Meme Stocks: Is MacroGenics Inc attractive for institutional investorsLayoff News & Smart Money Movement Alerts - baoquankhu1.vn
Will MacroGenics Inc. stock benefit from green energy trendsJuly 2025 Sentiment & Consistent Income Trade Ideas - Улправда
How supply chain issues affect MacroGenics Inc. stockQuarterly Performance Summary & Weekly High Return Opportunities - Улправда
Market Leaders: How supply chain issues affect MacroGenics Inc. stockWeekly Investment Report & Step-by-Step Trade Execution Guides - ulpravda.ru
Will MacroGenics Inc. stock gain from government policiesEarnings Overview Summary & Risk Controlled Swing Alerts - Улправда
Exploring Sarah Faizy's Journey in Life Sciences Leadership - BioBuzz
How MacroGenics Inc. stock performs in rising dollar environment2026 world cup usa national team quarterfinals young talents pressing system odds analysis breakdown - ulpravda.ru
There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues Despite A 26% Share Price Rise - simplywall.st
Macrogenics Inc Stock (MGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):